Workflow
AERA®
icon
Search documents
Integra LifeSciences(IART) - 2025 Q4 - Earnings Call Presentation
2026-02-26 13:30
EARNINGS PRESENTATION Q4 2025 February 26, 2026 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may ...
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Globenewswire· 2026-02-26 11:00
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share ...
Integra LifeSciences(IART) - 2025 Q2 - Earnings Call Presentation
2025-07-31 12:30
Financial Performance - Q2 2025 revenue was $415.6 million, a decrease of 0.6% compared to Q2 2024's $418.2 million[37] - Organic revenue decreased by 1.4% to $412.4 million in Q2 2025 compared to $418.2 million in Q2 2024[9, 38] - Adjusted EPS for Q2 2025 was $0.45, a decrease of 28.6% compared to $0.63 in Q2 2024[10, 37] - Adjusted EBITDA margin decreased by 290 bps to 17.1% in Q2 2025 compared to 20.0% in Q2 2024[10, 40] - Adjusted gross margin decreased by 450 bps to 60.7% in Q2 2025 compared to 65.2% in Q2 2024[11, 37] - Operating cash flow was $8.9 million with a negative 32.7% free cash flow conversion in Q2 2025[11, 39] Segment Performance - Codman Specialty Surgical Q2 2025 revenue was $304.0 million, a 0.7% increase, with organic growth down 0.3% to $300.9 million[13] - Tissue Technologies Q2 2025 revenue was $111.6 million, a decrease of 4.1%[18] Guidance - Q3 2025 reported revenue is projected to be between $410 million and $420 million, with organic growth between +7.3% and +9.9%[28] - Full year 2025 reported revenue is projected to be between $1.655 billion and $1.680 billion, with organic growth between +0.6% and +2.1%[29, 30]